NGS Multiplex Oligos Synthesis
Description
Currently, NGS has become the mainstream method for developing next-generation molecular diagnostic reagents. By using multiplex PCR technology to amplify targeted sequences, specific target genes can be obtained, making it one of the primary methods for constructing high-throughput sequencing libraries suitable for sequencing specific target regions.
SBS Genetech's NGS Multiplex Oligos Synthesis service operates through a fully automated quantitative dispensing workstation, ensuring precise and uniform quantification of each batch of primers. Additionally, customized production processes and QC have been developed specifically for the customer's downstream amplification library construction applications, fully ensuring amplification efficiency.
Service
Purification Method:
PAGE+ Purification: Each primer is purified using an independent system and disposable consumables, which minimizes the risk of mixing with other primers and effectively reduces the cross-contamination rate to below approximately 0.01%.
HPLC+ Purification: Before purifying each primer, chromatography columns undergo multiple special washing procedures to thoroughly remove residues. A reasonable interval is maintained between different primers to differentiate purification processes, minimizing the risk of mixing with other primers and effectively reducing the cross-contamination rate to below approximately 0.05%.
Desalting Purification
Base Range: 15-110 nt
Cycle and Price: Please Inquire
Shipment Content:
Single Tube or 96-Well Plate
Dry Powder or Solution
COA Document
Advantages
Precise quantification and dispensing
Extremely low base error rate
Purity guaranteed
With over 20 years of leading experience in oligo synthesis, SBS Genetech is recognized as one of the global major leading industry players in Oligonucleotide Synthesis by third-party market researchers. For more details, please visit Oligonucleotide Synthesis Services Market landscape, Top Competitor Analysis, Revenue, Sales With Forecast Data from 2022 to 2028.